Drug intelligence / Profile preview

aspirin + trametinib + dabrafenib

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy consisting of aspirin, trametinib, and dabrafenib. Dabrafenib is a BRAF inhibitor that blocks the activity of mutated BRAF V600E, while trametinib is a MEK inhibitor that blocks the activity of MEK enzymes. Together, they target the MAPK pathway in tumors with BRAF V600E mutations. The addition of aspirin to this combination is being investigated to potentially reduce fever (a common side effect of dabrafenib and trametinib) and possibly improve progression-free survival and overall survival outcomes.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)BRAF (B-Raf proto-oncogene, serine/threonine kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on aspirin + trametinib + dabrafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + trametinib + dabrafenib.

Explore the full profile